2008: Spondyloarthritis: Clinical Aspects and Treatment II
Search or Browse by Day

Spondyloarthritis: Clinical Aspects and Treatment II

Monday, October 27, 2008
1095
Cytokine and metalloproteinase profile In Psoriatic Arthritis patients treated with biologic therapy
1096
Golimumab Significantly Improves Physical Function, Health-Related Quality Of Life, Productivity, & Reduces Time Lost From Work For Caregivers In Patients With Active Psoriatic Arthritis
1097
Golimumab Administered Every Four Weeks As A Subcutaneous Injection In Psoriatic Arthritis: Nail, Enthesitis, And Dactylitis Response In The Randomized, Placebo-Controlled, GO-REVEAL Study
1098
Improvement in Psoriasis Is Associated With Long-Term Inhibition of Radiographic Progression in Patients With Psoriatic Arthritis Receiving Adalimumab (HUMIRA®)
1099
Adalimumab (HUMIRA®) Is Effective in Combination With Various Disease-Modifying Anti-Rheumatic Drugs for Joint and Skin Symptoms in Patients With Psoriatic Arthritis (PsA): Results of the STEREO Trial
1100
Clinical Remission and Good Clinical Responses in Patients With Psoriatic Arthritis (PsA) Treated With Adalimumab (HUMIRA®): Results of the STEREO Trial
1101
Sustained Clinical Improvement In Patients With Psoriatic Arthritis Under Etanercept Treatment : 3-years Results In Prospective Cohort
1102
Phase 2 Study of Ustekinumab, A Human IL-12/23 Monoclonal Antibody, in Psoriatic Arthritis: ACR Criteria Component Score Response Through Week 36
1103
An Open, Observational, Extension Study of a Three-Month, Randomized, Placebo-Controlled Trial to Assess the Long-Term Efficacy and Safety of Infliximab in Juvenile-Onset Spondyloarthritis (Jo-Spa)
1104
Long-Term Spinal Mobility in Patients With Ankylosing Spondylitis (AS) - 3-Year Results From the Adalimumab (HUMIRA®) Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS)
1105
Adalimumab (HUMIRA®) Is Highly Effective in Treating Patients With Ankylosing Spondylitis (AS) With Advanced Spinal Fusion
1106
Prediction of Response to Adalimumab by Magnetic Resonance Imaging (MRI) in the Treatment of Active Ankylosing Spondylitis
1107
Maintenance of Reduction in Disease Activity and Partial Remission in Patients With Ankylosing Spondylitis (AS) - 3-Year Results From the Adalimumab (HUMIRA®) Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS)
1108
Adalimumab Successfully Re-Treats and Maintains Long-Term Efficacy in Axial Spondyloarthritis (SpA) Patients Without Radiographic Sacroiliitis who Relapse Following Adalimumab Withdrawal
1109
Assessment of Patient-Reported Outcomes From a Randomized, Double-Blind Study of Etanercept and Sulphasalazine in Patients With Ankylosing Spondylitis
1110
A Drug Utilisation Observation (DUO) Study To Evaluate The Safety And Effectiveness Of Enbrel (etanercept) In Patients With Ankylosing Spondylitis (AS)
1111
Identification Of Serum Markers Associated With Improvement In Clinical Response Measures In Ankylosing Spondylitis Patients Treated With Golimumab
1112
Is There A Relationship Between Functionality And Productivity In Patients With Active Ankylosing Spondylitis? Results from the GO-RAISE Study
1113
Golimumab Significantly Improves Productivity in Patients with Active Ankylosing Spondylitis: Results from the Phase 3 GO-RAISE Study
1114
Golimumab Significantly Improves Health-Related Quality of Life in Patients with Active Ankylosing Spondylitis: Results from the Phase 3 GO-RAISE Study
1115
Improving Functionality Improves Sleep In Patients With Active Ankylosing Spondylitis: Results From The GO-RAISE Study
1116
Persistent Clinical Efficacy And Safety Of Inlifiximab In Patients With Ankylosing Spondylitis Over 7 Years - Evidence For Different Response To Anti-tnf-a Therapy
1117
MRI Assessment of Sacroiliac Joint Inflammation and Destruction and Spine Inflammation During Anti-TNF-Alpha Therapy - An Investigator Initiated 1-year Follow-up Study of Patients with Axial Spondyloarthritis
1118
Response To anti-TNF Therapy In Ankylosing Spondylitis Can Be Delayed And Is Predicted By BASDAI, HLA-B27 and Baseline CRP
1119
Five-Year Efficacy and Safety, Including Patient-Reported Outcomes, With Etanercept in Ankylosing Spondylitis
1120
Restoration Of Sexual Dysfunction By Anti-TNF-α Blockade In Male AS Patients
1121
Effect Of Infliximab On Body Composition, Bone Mineral Density And Bone Turnover In Patients With Active Psoriatic Arthritis
1122
Long-term Results of Infliximab Therapy: Different Survival Rates among Spondyloarthritis
1123
Golimumab Significantly Improves Physical Function In Patients With Active Ankylosing Spondylitis: Results From the Phase 3 GO-RAISE Study
1124
Golimumab Significantly Improves Sleep in Patients with Active Ankylosing Spondylitis: Results from the Phase 3 GO-RAISE Study
1125
Bone Biomarkers and Bone Density Measurements in Patients with Inflammatory Arthritis Prior to and Following anti-TNF Therapy
1126
Effects of TNF blockade treatment on work and associated variables in patients with Ankylosing Spondylitis
1127
Serum Levels Of Mmp-3 And Cathepsin K In Ankylosing Spondylitis Patients , And Evolution Under Anti Tnf-alpha Therapy
1128
Soft tissue changes induced by Repeated Serial Intra-Articular Etanercept Injections in the knee joints of patients with Resistant Knee Joint Synovitis
See more of: ACR Abstract Submission Poster Sessions
<< Previous Session Level | Next Session Level >>